|
시장보고서
상품코드
2035596
안과 질환 치료제 시장 규모, 점유율 및 성장 분석 : 질환별, 약제 분류별, 지역별 - 업계 예측(2026-2033년)Ophthalmic Disease Therapeutics Market Size, Share, and Growth Analysis, By Disease indication (Glaucoma, Retinal disease), By Drug Class (Anti-Inflammatory, Anti - infective), By Region - Industry Forecast 2026-2033 |
||||||
안과 질환 치료제 시장 규모는 2024년에 355억 4,000만 달러로 평가되었고, 2025년 377억 1,000만 달러에서 2033년까지 605억 6,000만 달러로 확대되어 예측 기간(2026-2033년)에 CAGR 6.1%를 보일 전망입니다.
안과 질환 치료제 시장은 전 세계 안질환 유병률 증가와 이에 따른 효과적인 시력 관리 솔루션에 대한 수요 증가로 인해 견조한 성장세를 보이고 있습니다. 시력 상실로 인한 경제적 손실은 막대한 영향을 미치고 있으며, 표적화된 치료법의 필요성이 대두되고 있습니다. 주요 제약사들은 망막질환을 대상으로 한 혁신적인 치료법 개발에 많은 투자를 하고 있으며, 시장 역학을 더욱 강화하는 새로운 치료법의 물결이 다가올 것으로 예측됩니다. 또한, 아시아 시장에서 저렴한 가격의 일반의약품의 등장으로 이 분야의 수익원이 확대될 것으로 예측됩니다. 다양한 치료제 카테고리 중에서도 현재 항염증제가 시장을 선도하고 있으며, 큰 점유율을 차지하고 있고, 향후 안과 질환 치료 분야에서도 그 우위를 유지할 태세를 갖추고 있습니다.
안과 질환 치료제 시장 성장 요인
안과 질환 치료제 시장은 Allergan plc(Allergan plc), F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc. 큰 영향을 받고 있습니다. 경쟁상황은 시장에 진입하는 중소규모의 지역기업이 증가함에 따라 고도로 세분화되어 있는 것이 특징입니다. 이러한 업체 간 다양성은 혁신을 촉진하고 환자가 이용할 수 있는 치료 옵션을 확대함으로써 이 부문의 성장을 가속하고 있습니다. 기존 기업과 신생 기업의 공존은 안과 질환 치료 솔루션의 진보를 지속적으로 추구할 수 있는 역동적인 환경을 조성하고 있으며, 이는 궁극적으로 효과적인 치료를 필요로 하는 사람들에게 혜택을 가져다 줄 수 있습니다.
안과 질환 치료제 시장 성장 억제요인
안과 질환 치료제 시장의 성장은 안과용 의약품 개발에 따른 제조 및 제제 공정이 장기간에 걸쳐 진행되기 때문에 큰 문제에 직면해 있습니다. 이러한 장기화는 기업이 제품을 효율적으로 시장에 출시할 수 있는 능력을 저해할 수 있습니다. 또한, 이러한 약물에 수반되는 잠재적인 부작용이 환자 및 의료진의 사용을 주저하게 만들 수 있어 시장 확대를 더욱 제한하는 요인으로 작용할 수 있습니다. 결과적으로 이러한 요인들은 안과 치료제 부문 전체에 제약이 되고 있으며, 업계 관계자들이 이러한 장벽을 극복하기 위해서는 혁신을 촉진하고 프로세스를 간소화하는 것이 필수적입니다.
안과 질환 치료제 시장 동향
안과 질환 치료제 시장은 안과 분야의 급속한 기술 발전에 힘입어 큰 변화를 맞이하고 있습니다. 첨단 영상 진단 기술과 최첨단 수술 도구와 같은 혁신은 안과 질환의 진단과 치료를 개선하고 있습니다. 백내장 수술에 펨토초 레이저의 도입은 이러한 추세를 상징하는 것으로, 보다 높은 정확도를 제공함과 동시에 합병증 위험을 최소화하고 있습니다. 또한, 최소침습 수술과 디지털 헬스 솔루션의 개발로 환자 진료가 변화하고 있으며, 인공지능(AI)도 진단의 정확도 향상에 활용되고 있습니다. 연구가 진행됨에 따라 이러한 기술들은 치료 결과를 향상시키고 안과 의료의 새로운 패러다임을 제시할 것으로 기대되고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 안과 질환 치료제 시장 규모 : 치료법별
세계의 안과 질환 치료제 시장 규모 : 질환 유형별
세계의 안과 질환 치료제 시장 규모 : 투여 경로별
세계의 안과 질환 치료제 시장 규모 : 유통 채널별
세계의 안과 질환 치료제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.06.01Ophthalmic Disease Therapeutics Market size was valued at USD 35.54 Billion in 2024 and is poised to grow from USD 37.71 Billion in 2025 to USD 60.56 Billion by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).
The ophthalmic disease therapeutics market is witnessing robust growth, driven by the rising global incidence of ocular diseases and the consequent need for effective vision care solutions. The economic impact of vision loss is significant, underscoring the urgency for targeted treatments. Major pharmaceutical companies are heavily investing in the development of innovative therapies aimed at retinal disorders, foreshadowing a wave of new treatment options that will further elevate market dynamics. Additionally, the rise of affordable over-the-counter medications in Asian markets is expected to enhance revenue streams within the sector. Among various therapeutic classes, anti-inflammatory medications currently lead the market, holding a substantial share and poised to sustain their dominance in the future landscape of ophthalmic disease treatments.
Top-down and bottom-up approaches were used to estimate and validate the size of the Ophthalmic Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Ophthalmic Disease Therapeutics Market Segments Analysis
Global Ophthalmic Disease Therapeutics Market is segmented by Drug Class, Dosage Form, Disease Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into anti-inflammatory, anti-infectives, Anti-VEGF, anti-glaucoma and others. Based on Dosage Form, the market is segmented into solid, liquid and semisolid. Based on Disease Indication, the market is segmented into glaucoma, dry eye disease, retinal diseases, allergy & infections and others. Based on Distribution Channel, the market is segmented into hospital pharmacies and retail & online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Ophthalmic Disease Therapeutics Market
The ophthalmic disease therapeutics market is significantly influenced by prominent players such as Allergan plc, F. Hoffmann-La Roche AG, and Regeneron Pharmaceuticals, Inc. The competitive landscape is characterized by a high degree of fragmentation, driven by an increasing number of small to mid-sized regional companies entering the market. This diversity among vendors enhances innovation and expands treatment options available to patients, thereby fostering growth within the sector. The presence of established firms alongside emerging players contributes to a dynamic environment where advancements in therapeutic solutions for ophthalmic diseases are continually being pursued, ultimately benefiting those in need of effective treatments.
Restraints in the Ophthalmic Disease Therapeutics Market
The growth of the ophthalmic disease therapeutics market faces significant challenges due to the lengthy manufacturing and formulation processes involved in developing ophthalmic drugs. These extended timelines can hinder the ability of companies to bring products to market efficiently. Additionally, the potential side effects associated with these medications may deter patients and healthcare providers from utilizing them, further limiting market expansion. As a result, these factors contribute to the overall constraints on the ophthalmic therapeutics sector, making it essential for industry players to innovate and streamline processes to overcome these hurdles.
Market Trends of the Ophthalmic Disease Therapeutics Market
The Ophthalmic Disease Therapeutics market is experiencing a significant trend driven by rapid technological advancements in the field of ophthalmology. Innovations such as advanced imaging techniques and state-of-the-art surgical tools are enhancing the diagnosis and treatment of eye diseases. The integration of femtosecond lasers in cataract surgeries epitomizes this trend, providing greater precision and minimizing the risk of complications. Additionally, the development of minimally invasive procedures and digital health solutions is transforming patient care, while artificial intelligence is being leveraged for improved diagnostics. As research progresses, these technologies are expected to bolster therapeutic outcomes and reshape ophthalmic care.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Technology Analysis
- Patent Analysis
Global Ophthalmic Disease Therapeutics Market Size by Therapy Type & CAGR (2026-2033)
- Market Overview
- Anti-VEGF Therapy
- Anti-Inflammatory Drugs
- Anti-Glaucoma Drugs
- Anti-Infective Drugs
- Others
Global Ophthalmic Disease Therapeutics Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Age-Related Macular Degeneration (AMD)
- Glaucoma
- Dry Eye Disease
- Diabetic Retinopathy
- Ocular Infections
- Others
Global Ophthalmic Disease Therapeutics Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Topical
- Oral
- Injectable
- Others
Global Ophthalmic Disease Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Global Ophthalmic Disease Therapeutics Market Size & CAGR (2026-2033)
- North America (Therapy Type, Disease Type, Route of Administration, Distribution Channel)
- US
- Canada
- Europe (Therapy Type, Disease Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Therapy Type, Disease Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Therapy Type, Disease Type, Route of Administration, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Therapy Type, Disease Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alcon Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch Health Companies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Santen Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Otsuka Holdings Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- EyePoint Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apellis Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kowa Company, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nidek Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
